S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Conditions:Other Indications, Other Indications, Blood Cancer, Lymphoma
Therapuetic Areas:Oncology, Other
Age Range:18 - Any
Start Date:April 2014
End Date:January 2023
Contact:Cara Laubach

Use our guide to learn which trials are right for you!

S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)

This phase I trial studies the side effects and best dose of inotuzumab ozogamicin when given
together with combination chemotherapy in treating patients with relapsed or refractory acute
leukemia. Immunotoxins, such as inotuzumab ozogamicin, can find cancer cells that express
cluster of differentiation (CD)22 and kill them without harming normal cells. Drugs used in
chemotherapy, such as cyclophosphamide, vincristine sulfate, and prednisone, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Giving inotuzumab ozogamicin together with combination chemotherapy may
kill more cancer cells.


I. To assess the safety of inotuzumab ozogamicin in combination with cyclophosphamide,
vincristine (vincristine sulfate) and prednisone (CVP) and to determine the maximum tolerated
dose (MTD) of inotuzumab ozogamicin in this regimen for patients with relapsed or refractory
CD22+ acute leukemia (B-cell acute lymphoblastic leukemia [B-ALL], mixed phenotype, and


I. To estimate the preliminary activity (response rate: complete remission [CR] + complete
remission with incomplete count recovery [CRi]) of this combination in the expansion cohort.

II. To estimate the frequency and severity of toxicities of this combination in this patient

OUTLINE: This is a dose-escalation study of inotuzumab ozogamicin.

Patients receive cyclophosphamide intravenously (IV) on day 1, vincristine sulfate IV on day
1, prednisone orally (PO) on days 1-5, and inotuzumab ozogamicin IV over 1 hour on days 1, 8,
and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease
progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 2 months for 1 year,
every 3 months for 1 year, and then every 6 months for 1 year.

Inclusion Criteria:

- Patients must have a diagnosis of relapsed or refractory CD22-positive acute leukemia
including B-ALL, mixed phenotype leukemia (biphenotypic), or Burkitt's leukemia based
on World Health Organization (WHO) classification; patients with bilineal leukemia are

- Patients must have evidence of acute leukemia in their peripheral blood or bone
marrow; patients must have >= 5% blasts in the peripheral blood or bone marrow within
14 days prior to registration; at least >= 20% of those blasts must be CD22-positive
(surface) based on local immunophenotyping and histopathology

- Patients must be refractory or have relapsed following prior induction therapy; a
standard induction regimen is defined as any program of treatment that includes
vincristine and prednisone or dexamethasone, cytarabine/anthracycline, or high dose

- For sites with the B1931022 pharmaceutical trial open, precursor B-cell ALL patients
from that site may be eligible for S1312 providing they meet the following criteria:

- Patient is in second salvage or more; OR

- Patient was treated on the standard of care arm of B1931022 and failed therapy

- Patients may have received prior allogeneic transplant or autologous transplant;
however, patients with prior allogeneic bone marrow transplant will be eligible only
if both of the following conditions are met:

- The transplant must have been performed >= 90 days prior to registration

- The patient must not have >= grade 2 acute graft versus host disease (GvHD) or
either moderate or severe limited chronic GvHD within 14 days prior to

- Patients known to have Philadelphia chromosome positive (Ph+) ALL must have either
failed treatment or been intolerant to treatment with at least two second or third
generation tyrosine kinase inhibitors

- Patients must not have received prior treatment with inotuzumab ozogamicin; previous
treatment with other anti-CD22 antibodies must have been completed at least 90 days
prior to registration

- Patients must have Zubrod performance status 0-2

- Patients must not have received any chemotherapy, investigational agents, or undergone
major surgery within 14 days prior to registration with the following exceptions:

- Monoclonal antibodies must not have been received for 1 week prior to

- Chimeric antigen receptor (CAR) T-cells must not have been received for 28 days
prior to registration.

- Steroids, hydroxyurea, vincristine, 6-mercaptopurine, methotrexate, thioguanine
and intrathecal chemotherapy are permitted within any time frame prior to
registration. FDA-approved TKIs may also be administered until 1 day prior to
start of study therapy (C1, D1).

- All drug-related toxicities must have resolved to =< grade 2

- Patients must not have a systemic bacterial, fungal, or viral infection that is not
controlled (defined as exhibiting ongoing signs/symptoms related to the infection and
without improvement despite appropriate antibiotics or other treatment)

- Patients must not have any other serious concurrent disease or have a history of
serious organ dysfunction or disease involving the heart, kidney, liver, or other
organ system that would put the patient at undue risk of undergoing therapy

- Patients must not have active central nervous system (CNS) involvement (by clinical
evaluation); patients with previous documented history of CNS involvement of acute
leukemia, or with clinical signs or symptoms consistent with CNS involvement of acute
leukemia, must have a lumbar puncture which is negative for CNS involvement of acute
leukemia; the lumbar puncture must be completed within 14 days prior to registration;
patients with no previous history of documented CNS involvement and with no clinical
signs or symptoms consistent with CNS involvement are not required to have completed a
lumbar puncture before registration; note that treatment with intrathecal therapy is
recommended during protocol treatment but CNS analysis during treatment is not

- Patients must have a peripheral blast count < 25,000/uL within 2 days prior to
registration; (treatment with hydroxyurea and steroids is permitted to bring the

- Patients must have serum creatinine =< 2 x institutional upper limits of normal (IULN)
within 7 days prior to registration

- Patients must have bilirubin =< 2 x IULN within 7 days prior to registration (unless
the bilirubin is primarily unconjugated)

- Patients must have < grade 2 neuropathy (sensory/motor) within 7 days prior to

- Patients must have serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate
pyruvate transaminase (SGPT) =< 2.5 x IULN within 7 days prior to registration

- Patients with a history of a serious allergic or anaphylactic reaction to humanized
monoclonal antibodies are not eligible

- Patients must not have a history of chronic or active hepatitis B or C infection;
patients must have negative hepatitis B and C serologies performed within 28 days
prior to registration

- Patients must not have evidence or history of veno-occlusive disease or sinusoidal
obstruction syndrome

- Patients must not have a cardiac ejection fraction < 45% or the presence of New York
Heart Association stage III or IV heart failure within 14 days prior to registration;
either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) may be used to
determine ejection fraction

- Patients must not have a myocardial infarction within 6 months prior to registration

- Patients must not have a history of clinically significant arrhythmia, prolonged
corrected QT (QTc) interval, or unexplained syncope not thought to be vasovagal in
nature within 6 months prior to registration

- Patients must not have a screening corrected QT using Fridericia's formula (QTcF)
interval > 500 milliseconds (by Fridericia calculation) based on the average of
triplicate electrocardiogram (EKG) performed within 7 days prior to registration; note
that triplicate EKG is required at other timepoints

- Patients must not have a history of chronic liver disease (or cirrhosis)

- Patients who are known to be human immunodeficiency virus (HIV)+ are eligible
providing they meet all of the following additional criteria within 28 days prior to

- CD4+ cells >= 350/mm^3 (nadir)

- Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on
combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on

- No zidovudine or stavudine as part of cART Patients who are HIV+ and do not meet
all of these criteria are not eligible for this study

- Patients with evidence of extramedullary disease at diagnosis will have computed
tomography (CT) scan of the chest, abdomen and pelvis to obtain baseline values within
28 days prior to registration

- Patients must have complete history and physical examination within 28 days prior to

- Patients must not be pregnant or nursing; women/men of reproductive potential must
have agreed to use an effective contraceptive method; a woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months; in addition to routine contraceptive methods, "effective
contraception" also includes heterosexual celibacy and surgery intended to prevent
pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures

- Prior malignancy other than acute leukemia is allowed, provided it is in remission and
there is no plan to treat the malignancy at the time of registration

- Pretreatment cytogenetics must be performed on all patients; collection of
pretreatment specimens must be completed within 14 days prior to registration to
S1312; specimens must be submitted to the site's preferred Clinical Laboratory
Improvement Amendments (CLIA)-approved cytogenetics laboratory; reports of the results
must be submitted as described; note that cytogenetics are required at other time

- Patients or their legally authorized representative must be informed of the
investigational nature of this study and must sign and give written informed consent
in accordance with institutional and federal guidelines

- As a part of the OPEN registration process the treating institution's identity is
provided in order to ensure that the current (within 365 days) date of institutional
review board approval for this study has been entered in the system

- Patients planning to enroll in this study must first have a slot reserved in advance
of the registration; all site staff will use OPEN to create a slot reservation
We found this trial at
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Margaret R. O'Donnell
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Duarte, CA
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Rochester, NY
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Aaron T. Gerds
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Cleveland, OH
Click here to add this to my saved trials
1504 Taub Loop
Houston, Texas 77030
(713) 873-2000
Principal Investigator: Martha P. Mims
Phone: 713-873-2000
Ben Taub General Hospital Located in the heart of the Texas Medical Center, Ben Taub...
Houston, TX
Click here to add this to my saved trials
875 Blake Wilbur Drive
Palo Alto, California 94304
Palo Alto, CA
Click here to add this to my saved trials